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Abstract
Bone is a dynamic tissue that is regulated by the  
activity of bone-resorbing osteoclasts and bone- 
forming osteoblasts. Excessive osteoclast forma-
tion causes diseases such as osteoporosis and  
rheumatoid arthritis. Natural substances may be  
useful as therapeutic drugs to prevent many di-
seases in humans because they avoid the many side  
effects of treatment with chemical compounds. Here  
we show that tanshinone IIA isolated from Salvia  
miltiorrhiza Bunge inhibits the receptor activator of 
NF-κB ligand (RANKL)-mediated osteoclast differen -
tiation of osteoclast precursors. Tanshinone IIA 
suppressed the expression levels of c-Fos and  
NFATc1 induced by RANKL. However, retrovirus- 
mediated overexpression of c-Fos induced the ex -
pression of NFATc1 despite the presence of tans-
hinone IIA and reversed the inhibitory effect of 
tanshinone IIA on osteoclast differentiation. Also, 
the introduction of osteoclast precursors with the  
NFATc1 retrovirus led to osteoclast differentiation in  
the presence of tanshinone IIA. Our results suggest 
that tanshinone IIA may have a role as a therapeutic  
drug in the treatment of bone disease such as  
osteoporosis.
Keywords: osteoclasts; tanshinone; Salvia miltior-
rhiza; drugs, Chinese herbal; osteoporosis; RANK 
ligand
Introduction
The balance between bone-resorbing osteoclasts 
and bone-forming osteoblasts is important to bone 
homeostasis. Many factors tightly regulate bone 
resorption and bone formation in vivo to maintain 
bone homeostasis (Suda et al., 1999; Boyle et al., 
2003). Bone erosion through excessive osteoclast 
formation is associated with alterations including 
estrogen deficiency and increases in inflammatory 
cytokines (Abu-Amer et al., 1997; Miyaura et al., 
2003) and in turn causes bone diseases such as 
rheumatoid arthritis, periodontal disease, osteoporo-
sis, and periprosthetic osteolysis. In addition, under 
certain conditions such as aging or prolonged smok-
ing, bone loss is caused by a defect in the bone- 
forming osteoblasts (Merkel et al., 1999; Liu et al., 
2001; Redlich et al., 2002). Most therapeutic drugs 
currently used to treat bone disease inhibit oste-
oclast formation or bone resorption. Consequently, 
there is a need for effective therapeutic drugs that 
improve the quality and quantity of bone.
    Osteoclasts, which are the cells primarily respon-
sible for bone resorption, are of hamatopoietic origin. 
Osteoclast differentiation is regulated by multiple 
processes through differential gene expression, one 
of which is characterized by the fusion of osteoclast 
precursors. Osteotropic agents including, IL-1, IL-6, 
IL-11, IL-15, IL-17, TNF- , PGE2 and PTH cause 
bone loss by increasing osteoclast formation (Suda 
et al., 1999; Hofbauer et al., 2000). Receptor ac-
tivator of NF- B ligand (RANKL), which is an 
essential osteoclastogenic cytokine, recruits TNF 
receptor-associated factor (TRAF) proteins through 
binding to its receptor, RANK, on the surface of 
osteoclast precursors. TRAFs activate various sig-
naling pathways, including c-Src, PI3-kinase/Akt, 
and MAPK (Anderson et al., 1997; Lee and Kim, 
2003). Several transcription factors, including NF- B, 
c-Fos, NFATc1, PU1 and MITF, are activated by 
RANKL and are important for osteoclast differen-
tiation (Teitelbaum et al., 2003). In particular, ex-
pression of c-Fos induced by RANKL plays an 
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essential role in the initiation of osteoclast differen-
tiation. c-Fos causes the expression of NFATc1 
during RANKL-mediated osteoclast differentiation 
(Matsuo et al., 2004). NFATc1 can induce osteoclast 
differentiation in the absence of RANKL. Thus, 
NFATc1 is an essential factor in osteoclast dif-
ferentiation (Takayanagi et al., 2002).
    Tanshinones are the major component of Danshen, 
the dried roots of Salvia miltiorrhiza Bunge (La-
biatae) that is used as a drug in traditional Chinese 
medicine (Hazra et al., 2004; Hur et al., 2005). Tan-
shinones have been widely used to treat menorrh-
algia, insomnia, coronary disease, and cardiovas-
cular disease (Takahashi et al., 2002; Han et al., 
2005). Furthermore, tanshinone IIA has been shown 
to be a potent antioxidant and to have anticancer 
activity against various cancer cells (Wu et al., 1998; 
Wang et al., 2005). Although tanshinone IIA has 
been used as a medicinal agent in the treatment of 
many diseases, its role in osteoclast-related bone 
disease remains unknown.
    We showed previously that tanshinone IIA greatly 
inhibits osteoclast differentiation and suppresses 
bone resorption through disruption of the actin ring 
(Kim et al., 2004). Here we examine the precise 
inhibitory mechanism of tanshinone IIA on RANKL- 
induced osteoclast differentiation. This study shows 
that tanshinone IIA prevents osteoclast differen-
tiation by inhibiting c-Fos and NFATc1 expression.
Materials and Methods
Reagents
Tanshinone IIA was isolated from Danshen as des-
cribed previously (Kim et al., 2004). Recombinant 
human RANKL and macrophage CSF (M-CSF) were 
purchased from PeproTech EC (London, England). 
Antibody to c-Fos was obtained from Cell Signaling 
Technology (Beverly, MA). Antibodies to NFATc1 and 
actin were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). pMX-IRES-EGFP, pMX- 
c-Fos-IRES-EGFP, and pMX-NFATc1-IRES-EGFP 
vectors were kindly provided by Dr. Nacksung Kim 
(University of Chonnam).
Isolation of osteoclast precursors and
osteoclastogenesis
Osteoclast precursors were prepared as previously 
described with some modification (Park et al., 2005). 
Briefly, bone marrow cells were obtained from the 
tibia and femur of 5-week-old male ICR mice. Bone 
marrow cells were suspended in -MEM (Welgene) 
containing 10% FBS (Gibco BRL) and antibiotics 
(Sigma) and were cultured for 1 day in the presence 
of M-CSF (10 ng/ml). After 1 day, nonadherent cells 
were seeded on a 10-cm bacterial culture dishes 
and cultured for 3 days in the presence of M-CSF 
(30 ng/ml) and further adherent cells were used as 
osteoclast precursors. For the osteoclast differen-
tiation assay, osteoclast precursors were cultured for 
4 days with M-CSF (30 ng/ml) and RANKL (50 ng/ml) 
in the presence or absence of tanshinone IIA (10 g/ 
ml). Alternatively, calvarial osteoblasts were iso-
lated from 1-day-old ICR mouse as described pre-
viously (Kwak et al., 2004). Briefly, mouse calvariae 
were obtained from pericranium and washed with 
HBSS containing antibiotics. Calvariae were diges-
ted 5 times for 15 min in 0.1% collagenase and 0.2% 
dispase. Cells were cultured for 3 days and adherent 
cells were used as osteoblasts. Osteoblasts and 
bone marrow cells were cocultured for 6 days with 
TNF-  (20 ng/ml), IL-1  (10 ng/ml), or LPS (1 µg/ml) 
in the presence or absence of tanshinone IIA (10 
µg/ml).
Reverse transcription (RT)-PCR analysis
For RT-PCR assays, total RNA was isolated by 
using the TRI reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. Two 
micrograms of total RNA from each sample was 
reverse transcribed in a mixture containing oligo dT 
primer, dNTP, reverse transcriptase buffer, RNase 
out, DTT, and Superscript II reverse transcriptase 
(Invitrogen). cDNA (1 l) was amplified by PCR to 
generate the genes listed as follows: RANK sense, 
5'-CACAGACAAATGCAAACCTTG-3; RANK antisen-
se, 5'-GTGTTCTGGAACCTATCTTCCTCC-3'; c-Fms 
sense, 5'-AGCTCTCAGTACTTCAGGGC-3'; c-Fms 
antisense, 5'-CAAAGGCACCGGCTCCTAGA-3'; c-Fos 
sense, 5'-CTGGTGCAGCCCACTCTGGTC-3'; c-Fos 
antisense, 5'-CTTTCAGCAGATTGGCAATCTC-3'; NFATc1 
sense, 5'-CAACGCCCTGACCACCGATAG-3'; NFATc1 
antisense, 5'-GGCTGCCTTCCGTCTCATAGT-3'. PCR 
amplification was performed for 20-25 cycles at 94oC 
for 30 s, 56-58oC for 30 s, and 72oC for 30 s, follow-
ed by a 7 min at 72oC. PCR product were separated 
on a 1% agarose gels and visualized by staining 
with ethidium bromide. Densitometric values for 
each band were quantified by using the Image 
Pro-plus program version 4.0 (Media Cybernetics).
Immunoblotting
Cells were lysed in lysis buffer (50 mM Tris-Cl, 150 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM NaF, 
1 mM Na3VO4, and 1% deoxycholate) containing 
protease inhibitors. Cell lysates were centrifuged at 
16,000 × g for 20 min, and total protein was mea-
sured with a DC Protein Assay kit (Bio-Rad, Her-
cules, CA). Equal amounts of protein were electro-
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phoresed by 10-15% SDS-PAGE and transferred to 
a polyvinylidene difluoride membrane (Amersham 
Biosciences, Piscataway, NJ). Protein levels were 
analyzed by immunoblotting with antibodies to c-Fos, 
NFATc1, and actin that were detected by using 
enhanced chemiluminescent reagents.
Retrovirus preparation
For retrovirus preparation, Plat E packaging cells 
were transiently transfected with pMX-IRES-EGFP, 
pMX-c-Fos-IRES-EGFP, or pMX-NFATc1-IRES-EGFP 
vectors by using Lipofectamine 2000 as recom-
mended by the manufacturer. Six to eight hour after 
transfection, the medium was replaced with DMEM 
containing 10% FBS and antibiotics. Culture super-
natant fluid containing retrovirus was collected 48 h 
after transfection and was used as a retrovirus.
Luciferase assay
NFATc1 luciferase reporter gene was kindly pro-
vided by Dr. Nacksung Kim (University of Chonnam). 
HEK 293T cells were plated in 24-well plates and 
transiently transfected with RANK and the AP-1 or 
NFATc1 leuciferase reporter genes using Lipofecta-
mine 2000 and incubated for 24 h with or without 
tanshinone IIA. The cells were lysed with lysis buffer, 
and the luciferase activities were measured using a 
luciferase reporter assay system (Promega, Madi-
son, WI).
Figure 1. Inhibition of RANKL-mediated osteoclastogenesis by tanshinone IIA. (A) Osteoclast precursors were cultured with M-CSF (30
ng/ml) and RANKL (50 ng/ml) for 4 days in the presence or absence of tanshinone IIA. Cells were fixed in 10% formalin, permeabilized 
with 0.1% Triton X-100, and stained with TRAP solution. (B) TRAP+ cells containing five or more nuclei were counted as multinucleated 
osteoclasts. Data from three experiments are presented as mean ± S.D. *P＜ 0.01, significantly different from the control. (C) 
Osteoclast precursors were incubated with M-CSF (30 ng/ml) in the presence or absence of tanshinone IIA for the indicated time. The 
mRNA expression of the indicated genes was analyzed by RT-PCR.
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Statistical analysis
All quantitative results are presented as means ±
S.D. Statistical significance was analyzed by using 
Student’s t test. P values ＜ 0.05 were considered to 
be statistically significant and are defined with an 
asterisk.
Results
Tanshinone IIA inhibits RANKL-mediated osteoclast 
differentiation
Tanshinone IIA greatly suppressed RANKL-mediated 
osteoclast differentiation in osteoclast precursors 
(Figure 1A and B). We also examined the alteration 
of expression of RANK and c-Fms, which act as 
receptors for RANKL and M-CSF, respectively. Os-
teoclast precursors were treated with DMSO or 
tanshinone IIA for various times in the presence of 
M-CSF. M-CSF increased RANK mRNA expression 
in osteoclast precursors, as previously reported (Mi-
yamoto et al., 2000). Tanshinone IIA did not change 
the expression of RANK and c-Fms in osteoclast 
precursors (Figure 1C). These results suggest that 
tanshinone IIA does not inhibit signaling pathways, 
which involved in M-CSF-induced RANK expression 
and that tanshinone IIA may affect RANKL-induced 
signaling involved in osteoclastogenesis.
Tanshinone IIA suppresses c-Fos and NFATc1
expression induced by RANKL
Osteoclast differentiation is regulated through the 
induction of various genes in response to RANKL. In 
particular, c-Fos and NFATc1 are well known to play 
an essential role in the differentiation of osteoclast 
precursors (Takayanagi et al., 2002; Hirotani et al., 
2004). We thus studied whether tanshinone IIA 
regulates the expression of c-Fos and NFATc1 in 
response to RANKL. Osteoclast precursors were 
pretreated with DMSO or tanshinone IIA (10 g/ml) 
and further stimulated with RANKL (100 ng/ml) for 
various times in the presence of M-CSF. Densito-
Figure 2. Inhibition of RANKL-induced c-Fos and 
NFAT2 expression in osteoclast precursors by tan-
shinone IIA. (A) Osteoclast precursors were pre-
treated for 1 h with or without tanshinone IIA and 
then stimulated with RANKL (100 ng/ml) in the 
presence of M-CSF (30 ng/ml) for the indicated 
time. Total RNA was isolated and reverse tran-
scribed, and the mRNA expression of the indicated 
genes was measured by RT-PCR. (B) Cells were 
stimulated as in (A). Cells lysates were immuno-
blotted with antibodies to p38 and NFATc1 to detect 
c-Fos and NFATc1. Band intensity was quantified 
by using an Image Pro-plus program version 4.0 
(Media Cybernetics).
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Figure 3. Overexpression of c-Fos reverses the inhibitory effect of tanshinone IIA on osteoclast differentiation. pMX-IRES-EGFP or pMX- 
c-Fos-IRES-EGFP vectors were transiently transfected into Plat E cells. After 6-8 h, the medium was changed and the culture supernatant fluid was 
used as a retrovirus as described in Materials and methods. (A) Osteoclast precursors were infected with control or c-Fos retrovirus for 7 h in the 
presence of M-CSF (30 ng/ml) and polybrene (6 g/ml). The medium was replaced and further treated with or without tanshinone IIA (10 g/ml) for 
48 h. Cell lysates were immunoblotted with antibodies to c-Fos and NFATc1. (B) HEK 293T cells were seeded in a 24-well plates and transiently 
transfected with AP-1 reporter gene or RANK and AP-1 reporter gene. Cells were incubated for 24 h in the presence or absence of tanshinone IIA. 24 
h after transfection, the cells were lysed and assayed for luciferase activity using a luciferase reporter assay system. (C) HEK 293T cells were tran-
siently transfected with NFATc1 reporter gene or RANK and NFATc1 reporter gene. Luciferase assay was performed as above. (D) Osteoclast pre-
cursors were infected with control or c-Fos retrovirus as in (A) and were then cultured for 5 days with M-CSF (30 ng/ml) and RANKL (100 ng/ml) in 
the presence or absence of tanshinone IIA (10 g/ml). Cells were fixed and stained for TRAP. (E) TRAP+ cells were counted as osteoclasts.
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metric value of RT-PCR normalized by GAPDH 
intensity showed that tanshinone IIA greatly inhibited 
the expression of NFATc1 mRNA and slightly sup-
pressed c-Fos mRNA expression in response to 
RANKL (Figure 2A). Consistent with the results of 
the RT-PCR analyses, protein levels of c-Fos and 
NFATc1 were increased in response to RANKL, but 
the expression of both c-Fos and NFATc1 was 
significantly inhibited by tanshinone IIA (Figure 2B). 
Thus, tanshinone IIA may inhibit osteoclast differen-
tiation by inhibiting c-Fos and NFATc1 expression in 
response to RANKL.
Inhibition of osteoclast differentiation by tanshinone 
IIA is reversed by overexpression of c-Fos
To elucidate the mechanism by which tanshinone IIA 
inhibits c-Fos and NFATc1 expression, we infected 
osteoclast precursors with control retrovirus or c-Fos 
retrovirus for 7 h in the presence of M-CSF (30 
ng/ml) and polybrene (6 g/ml). The medium was 
replaced with fresh -MEM containing 10% FBS and 
antibiotics and further cultured for 48 h with M-CSF 
in the presence or absence of tanshinone IIA. As 
shown in Figure 3A, the expression of c-Fos and 
NFATc1 induced by c-Fos retroviral infection com-
Figure 4. Overexpression of NFATc1 reverses the effect of tanshinone IIA in 
osteoclast differentiation. Plat E cells were transiently transfected with 
pMX-NFATc1-IRES-EGFP or pMX-IRES-EGFP vectors to obtain retrovirus. 
(A) Osteoclast precursors were infected with control retrovirus or NFATc1 
retrovirus for 7 h in the presence of M-CSF (30 ng/ml) and polybrene (6 
g/ml). Infected cells were visualized by confocal microscopy. (B) Osteoclast 
precursors were infected with control or NFATc1 retrovirus as in (A) and then 
cultured for 5 days with M-CSF (30 ng/ml) and RANKL (100 ng/ml) in the 
presence or absence of tanshinone IIA (10 g/ml). Cells were fixed and 
stained for TRAP. (C) TRAP+ cells were counted as osteoclasts.
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pletely rescued the inhibitory effect of tanshinone 
IIA. Furthermore, we examined for direct evidence 
that tanshinone IIA inhibits the c-Fos and NFATc1 
transcriptional activity by cotransfecting HEK 293T 
cells with RANK and the AP-1 or NFATc1 promoter- 
luciferase gene. RANK-mediated AP-1 promoter ac-
tivity was inhibited in the presence of tanshinone IIA. 
However, tanshinone IIA does not inhibit NFATc1 
transcriptional activity (Figure 3B and C). These re-
sults suggest that tanshinone IIA specifically regul-
ates c-Fos expression in response to RANKL rather 
than regulating NFATc1 expression.
    Next we investigated whether overexpression of 
c-Fos in osteoclast precursors could rescue the 
inhibition of osteoclast differentiation by tanshinone 
IIA. After infection with control or c-Fos retrovirus, 
cells were cultured for 5 days with M-CSF and 
RANKL in the presence or absence of tanshinone 
IIA. Osteoclast differentiation was significantly higher 
after infection of osteoclast precursors with c-Fos 
retrovirus than after infection with control retrovirus 
in the presence of tanshinone IIA (Figure 3D and E). 
These results suggest that tanshinone IIA sup-
presses osteoclast differentiation through inhibition 
of c-Fos expression.
NFATc1 rescues osteoclast differentiation in the  
presence of tanshinone IIA
The induction of NFATc1 in osteoclast precursors is 
essential for osteoclast differentiation and is re-
gulated by both c-Fos and the calcium/calcineurin 
pathways (Takayanagi et al., 2002). Inhibition of 
NFATc1 by tanshinone IIA is associated with inhi-
bition of c-Fos in response to RANKL. Therefore, we 
examined whether NFATc1 could overcome the 
inhibition of osteoclast differentiation caused by 
tanshinone IIA. After infection of osteoclast precur-
sors with control and NFATc1 retrovirus, the medium 
was replaced with fresh -MEM containing 10% FBS 
and antibiotics and further cultured for 48 h with 
M-CSF. GFP-expressed cells were visualized by 
confocal microscopy, and the infection efficiency of 
the control and NFATc1 retroviruses was more than 
90% (Figure 4A). Osteoclast precursors were infec-
ted with control or NFATc1 retrovirus in the presence 
of M-CSF (30 ng/ml) and polybrene (6 g/ml) and 
further cultured for 5 days with M-CSF (30 ng/ml) 
and RANKL (50 ng/ml) in the presence or absence 
of tanshinone IIA (10 g/ml). As shown in Figure 4B 
and C, overexpression of NFATc1 rescued the block-
age of osteoclast differentiation in the presence of 
tanshinone IIA. Thus, the inhibitory effects of tans-
hinone IIA on osteoclast differentiation result from 
the decrease in NFATc1 by inhibition of c-Fos.
Discussion
Bone is a dynamic tissue that is maintained by the 
balance between bone formation and bone resor-
ption; this balance can be easily upset by chronic 
inflammation, menopause, and aging (Karsenty et 
al., 2002). Bone erosion results from excessive os-
teoclast formation rather than damage to osteoblast 
activity. Therefore, the development of drugs that act 
to regulate osteoclast formation is important to 
prevent bone disease. Previously, we reported that 
tanshinone IIA significantly inhibits the differentiation 
of osteoclast precursors mediated by RANKL (Kim et 
al., 2004). Two key factors, RANKL and M-CSF, 
regulate the expression of various genes in osteo-
clast precursors by binding to their receptors, RANK 
and c-Fms, respectively, the levels of which are 
important in osteoclast differentiation. In particular, 
expression of c-Fms is a crucial feature of osteoclast 
progenitors. The addition of M-CSF to osteoclast 
progenitors causes the expression of RANK; there-
by, RANKL induces differentiation into osteoclasts 
(Miyamoto et al., 2000). Although tanshinone IIA 
inhibits osteoclast differentiation, it does not alter the 
expression of RANK or c-Fms (Figure 1). These 
results suggest that tanshinone IIA suppresses 
osteoclast differentiation induced by RANKL.
    A member of the TNF superfamily, RANKL media-
tes multiple signaling pathways via RANK in os-
teoclast precursors and activates critical transcrip-
tion factors for osteoclast differentiation and function 
(Suda et al., 1999; Boyle et al., 2003; Lee and Kim, 
2003). One such transcription factor is NFATc1, 
which is expressed in osteoclast precursors through 
Ca2+ oscillation and c-Fos in response to RANKL 
and that is required for the regulated expression of 
many genes, including TRAP, calcitonin receptor, 
and cathepsin K (Takayanagi et al., 2005). Thus, re-
gulation of NFATc1 expression in osteoclast precur-
sors has significant consequences for bone disorder 
therapeutics. We found that the inhibition of os-
teoclast differentiation by tanshinone IIA coincides 
with regulation of c-Fos and NFATc1. Tanshinone 
IIA slightly inhibits the mRNA expression of endo-
genous c-Fos induced by RANKL but completely 
inhibits the expression of the c-Fos protein (Figure 
2). Therefore, we hypothesized that down-regulation 
of c-Fos protein is involved in c-Fos mRNA degra-
dation. However, tanshinone IIA did not affect the 
expression of exogenous c-Fos induced by c-Fos 
retroviral infection (Figure 3) or the stability of c-Fos 
mRNA (data not shown). These results indicate that 
tanshinone IIA does not affect the mRNA or protein 
stability of c-Fos or its posttranscriptional regulation. 
Our previous results indicate that tanshinone IIA
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causes alteration of RANKL-induced signaling path-
ways including ERK (Kim et al., 2004), a known 
signaling pathway to regulate c-Fos expression 
(Whitmarsh et al., 1995). Thus, this altered signaling 
pathway is related to inhibitory effect of tanshinone 
IIA on RANKL-induced c-Fos expression.
    c-Fos, however, plays an important role in the 
expression of NFATc1, which is an essential factor 
for osteoclast differentiation. We also found that 
overexpression of c-Fos caused by c-Fos retroviral 
infection can rescue NFATc1 expression in the 
presence of tanshinone IIA (Figure 3). However, the 
inhibitory effect of tanshinone IIA on RANKL-me-
diated osteoclast differentiation was not entirely 
rescued by c-Fos or NFATc1 administration. Actually, 
NFATc1 is essential for osteoclast differentiation but 
is not sufficient for osteoclast differentiation in the 
absence of RANKL. Other transcription factors, in-
cluding NF- B, MITF, activator protein 1, and PU1, 
are required for osteoclast differentiation (Teitelbaum 
et al., 2003; Walsh et al., 2003). These results in-
dicate that osteoclast differentiation induced by RANKL 
requires several transcription factors for cooperating 
with NFATc1. We showed previously that tanshin-
one IIA suppresses Akt, ERK, and NF- B activation 
in response to RANKL (Kim et al., 2004). Thus, we 
conclude that tanshinone IIA prevents functional 
cooperation between NFATc1 and NF- B in respon-
se to RANKL.
    In summary, we investigated the effect of tans-
hinone IIA on osteoclast formation. Tanshinone IIA 
greatly inhibits osteoclast formation by inhibiting the 
expression of c-Fos and NFATc1 induced by RANKL. 
Taken together, our results suggest that tanshinone 
IIA probably plays an important role in inhibiting 
bone loss by preventing osteoclast formation.
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